Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026)

At the end of FY2025, Vor Biopharma's Accumulated Expenses came in at $19.76 million, up 53.3% from FY2024.

• Annual Accumulated Expenses has increased for five consecutive years, with a five-year compound annual growth rate of 25.9% (FY2020 to FY2025).
• In prior years, Vor Biopharma's Accumulated Expenses was $12.89 million in FY2024 (+18.5%), $10.88 million in FY2023 (+37.9%), $7.89 million in FY2022 (+24.5%) and $6.34 million in FY2021 (+1.2%).
• Quarterly Accumulated Expenses has run from a low of $5.49 million in Q1 2023 to a high of $58.1 million in Q2 2025 over five years.
• On a year-over-year basis, Accumulated Expenses increased in six of the last eight quarters, with growth averaging 106.2%.
• The strongest year-over-year quarter for Accumulated Expenses in the past five years was Q2 2025, with growth of 658.9%; the weakest was Q2 2026, with a decline of 64.8%.
• According to Business Quant data, Accumulated Expenses for the three prior quarters was $14.73 million (Q1 2026), $19.76 million (Q4 2025) and $17.7 million (Q3 2025).